The HISPANEL, including close to 100 recurrent mutations, has been applied in breast cancer patients from Mexico, Colombia, Peru and Brazil, with diverse results [29–32], due to the diversity of BRCA1 and BRCA2 mutations among different Latin American populations, and the variable criteria to select the patients to be analyzed. This evidence concerns the gene BRCA1 and breast cancer.